{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:36:52Z","timestamp":1775871412488,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":134,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.nefroe.2021.06.010","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T12:43:13Z","timestamp":1674909793000},"page":"578-584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tocilizumab in the treatment of active chronic humoral rejection resistant to standard therapy"],"prefix":"10.1016","volume":"42","author":[{"given":"Betty","family":"Chamoun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"S\u00e1nchez-Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina B.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Gabaldon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Perell\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Sellar\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Moreso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ser\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2021.06.010_bib0005","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0010","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1993.03510110079036","article-title":"Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients","volume":"270","author":"Port","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0015","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1681\/ASN.2017121296","article-title":"Any progress in the treatment of antibody-mediated rejection?","volume":"29","author":"Budde","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0020","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/tri.13436","article-title":"The therapeutic challenge of late antibody-mediated kidney allograft rejection","volume":"32","author":"B\u00f6hmig","year":"2019","journal-title":"Transpl Int"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0025","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/j.1600-6143.2009.02800.x","article-title":"De Novo Donor-Specific Antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure","volume":"9","author":"Hidalgo","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00106","article-title":"The role of the endothelium during antibody-mediated rejection: from victim to accomplice","volume":"9","author":"Cross","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0035","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantion Society Working Group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0040","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0045","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0050","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial","volume":"17","author":"Kulkarni","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0060","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0065","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/TP.0000000000001452","article-title":"Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade","volume":"101","author":"Jordan","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0070","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (Anti\u2013Interleukin-6 Receptor Monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0075","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0080","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/TP.0000000000003247","article-title":"CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection","volume":"105","author":"Doberer","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0085","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1097\/TP.0000000000000741","article-title":"A phase I\/II trial of the interleukin-6 receptor\u2013specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.nefroe.2021.06.010_bib0090","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000988","article-title":"Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients","volume":"6","author":"Pottebaum","year":"2020","journal-title":"Transplant Direct"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0095","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/ajt.16391","article-title":"Do anti\u2010IL\u20106R blockers have a beneficial effect in the treatment of antibody\u2010mediated rejection resistant to standard therapy after kidney transplantation?","volume":"21","author":"Massat","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0100","doi-asserted-by":"crossref","first-page":"663","DOI":"10.34067\/KID.0000182019","article-title":"Lack of histological and molecular signature response to tocilizumab in kidney transplants with chronic active antibody mediated rejection: a case series","volume":"1","author":"Kumar","year":"2020","journal-title":"Kidney360"},{"key":"10.1016\/j.nefroe.2021.06.010_bib0105","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1681\/ASN.2020071106","article-title":"A randomized clinical trial of Anti\u2013IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection","volume":"32","author":"Doberer","year":"2021","journal-title":"J Am Soc Nephrol"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T17:16:41Z","timestamp":1730049401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251423000147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2013251423000147"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2021.06.010","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab in the treatment of active chronic humoral rejection resistant to standard therapy","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2021.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2021.06.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}